Senores reports 29.83% operating margin in Q1FY27
Operating profit was Rs 53.76 cr, while management highlighted product additions, manufacturing efficiency and expansion capacity at Apnar Pharma.
Filed 27 Jul 2026, 18:24 IST · after market close · Senores Pharmaceuticals Ltd (SENORES)
Key takeaways
- Senores delivered a 29.83% consolidated operating margin in Q1FY27, with Rs 53.76 cr of operating profit on Rs 180.21 cr of revenue.
- Net profit was Rs 30.45 cr after Rs 7.17 cr of interest, Rs 9.94 cr of depreciation and a 22.83% tax rate.
- The 29.83% operating margin matched the Healthcare median across 9 reported peers, ranking Senores fifth from the bottom.
Price around the results
Q1FY27 operating profit clears the below-the-line burden
The consolidated quarter produced Rs 53.76 cr of operating profit from Rs 180.21 cr of revenue, implying a 29.83% operating margin. Profit before tax was Rs 39.46 cr after Rs 7.17 cr of interest and Rs 9.94 cr of depreciation, partly offset by Rs 2.81 cr of other income. Net profit came in at Rs 30.45 cr, with EPS of Rs 6.61.
Margin is in line with the reported Healthcare peer set
Senores' 29.83% operating margin matched the median for the 9 Healthcare peers that had reported the same quarter. That placed the company fifth from the bottom in the peer comparison. The presentation said manufacturing and cost efficiency remain a focus for sustainable margin growth and expansion.
Management points to products and capacity as growth pillars
Management said additions to approved and pipeline products provide high-growth visibility for years to come. The company said its Apnar Pharma plant sits on a larger plot with land available for future expansion. Management also said 5+ products are in development at its API plants.
Results were filed after market close
Senores filed the consolidated results at 18:24 IST on 27 Jul 2026, after market close. This note therefore does not assess an immediate stock reaction.
Q1FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 |
|---|---|
| Revenue | ₹180 cr |
| Other income | ₹3 cr |
| Expenses | ₹126 cr |
| Operating profit | ₹54 cr |
| Operating margin (%) | 29.83% |
| Interest | ₹7 cr |
| Depreciation | ₹10 cr |
| Profit before tax | ₹39 cr |
| Tax | ₹9 cr |
| Net profit | ₹30 cr |
| EPS (₹) | ₹6.61 |
Operating margin of 29.83% compares with a Healthcare sector median of 29.83% across 9 peers that have reported Q1FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
Guidance & outlook
- The company reports robust additions to approved and pipeline products, providing high-growth visibility for years to come.
Expansion
- The company’s Apnar Pharma plant has a larger plot with land available for future expansion.
New products
- The company has 5 or more products in development at its API plants.
New initiatives
- The company is focusing on manufacturing and cost efficiency to enable sustainable margin growth and expansion.
What to watch
- Whether consolidated operating margin remains at or above 29.83%.
- Progress on the 5+ API products in development cited by management.
- Updates on expansion at the Apnar Pharma plant, where management said land is available for future expansion.